CIA
SUPN icon

Capital Impact Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Capital Impact Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,598
Closed -$469K – 161
2023
Q2 		$469K Hold
15,598
– – 0.52% 96
2023
Q1 		$565K Sell
15,598
-6,692
-30% -$257K 0.69% 58
2022
Q4 		$795K Hold
22,290
– – 0.78% 30
2022
Q3 		$760K Sell
22,290
-232
-1% -$7.55K 0.76% 35
2022
Q2 		$651K Sell
22,522
-3,388
-13% -$97K 0.6% 57
2022
Q1 		$837K Buy
+25,910
New +$794K 0.61% 63
2021
Q4 		– Sell
-48,500
Closed -$1.29M – 141
2021
Q3 		$1.29M Hold
48,500
– – 0.51% 83
2021
Q2 		$1.49M Hold
48,500
– – 0.48% 85
2021
Q1 		$1.27M Buy
+48,500
New +$1.36M 0.44% 80
2020
Q4 		– Sell
-83,632
Closed -$1.74M – 120
2020
Q3 		$1.74M Hold
83,632
– – 0.52% 86
2020
Q2 		$1.99M Hold
83,632
– – 0.66% 73
2020
Q1 		$1.5M Buy
83,632
+5,001
+6% +$105K 0.63% 77
2019
Q4 		$1.86M Buy
78,631
+2,866
+4% +$69.6K 0.66% 88
2019
Q3 		$2.08M Buy
75,765
+12,846
+20% +$381K 0.79% 48
2019
Q2 		$2.02M Buy
62,919
+18,254
+41% +$625K 0.74% 51
2019
Q1 		$1.45M Hold
44,665
– – 0.64% 89
2018
Q4 		$1.45M Buy
44,665
+3,661
+9% +$157K 0.62% 92
2018
Q3 		$2.05M Buy
41,004
+3,239
+9% +$160K 0.7% 59
2018
Q2 		$2.2M Sell
37,765
-5,260
-12% -$272K 0.82% 35
2018
Q1 		$1.97M Buy
43,025
+13,845
+47% +$578K 0.81% 40
2017
Q4 		$1.16M Hold
29,180
– – 0.5% 110
2017
Q3 		$1.17M Hold
29,180
– – 0.52% 118
2017
Q2 		$1.26M Sell
29,180
-11,179
-28% -$398K 0.57% 81
2017
Q1 		$1.26M Buy
+40,359
New +$1.08M 0.5% 110
2015
Q1 		– Sell
-16,796
Closed -$139K – 295
2014
Q4 		$139K Hold
16,796
– – 0.07% 183
2014
Q3 		$146 Hold
16,796
– – ﹤0.01% 150
2014
Q2 		$184K Buy
+16,796
New +$150K 0.14% 99

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Impact Advisors's SUPN Position: Q3 2023 in Review

Capital Impact Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2023, closing a stake of 15,598 shares — an estimated $469K sold.

Capital Impact Advisors first reported a position in SUPN in Q2 2014 and held it in 27 quarters. The position peaked at $2.2M in Q2 2018. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

  • Capital Impact Advisors reported no remaining Supernus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Capital Impact Advisors sold 15,598 Supernus Pharmaceuticals shares in Q3 2023, an estimated $469K.
  • Capital Impact Advisors first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 27 quarters.
  • Capital Impact Advisors's Supernus Pharmaceuticals position peaked at $2.2M in Q2 2018.
  • 238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on Capital Impact Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.